Under one in 10 individuals that would benefit from GLP-1 drugs including Wegovy are able to get them, states the WHO as it releases its first guidance on the medications.
Considering more than one billion individuals worldwide currently classified as obese, it is advocating for increased and just availability to these injectable treatments.
Based on estimates, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.
"Our latest guidelines affirms that excess weight is a lifelong illness that can be managed with holistic and lifelong support," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are key obstacles to broad availability to the jabs that can assist patients in reducing significant body mass, notes the organization.
Skinny Jab Supply Crisis
Even in the current most optimistic case, the manufacturing of such drugs would only suffice for around 100 million people – less than 10% of those who need them, per the health organization.
The guideline encourages countries and companies to widen access, by measures such as licensing agreements.
A patent on the active ingredient – the primary component of a leading brand – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Injections Function
GLP-1 drugs imitate a natural hormone to delay gastric emptying, reduce hunger and enhance satiety so users reduce food intake.
Individuals typically begin shedding pounds within a few weeks of commencing the weekly injections.
Studies suggests patients may put most of the weight back on a year later of stopping the medication, as their typical food cravings return.
Being overweight or obese increases your risk for developing medical conditions, such as type 2 diabetes, heart disease, brain attack, and some cancers.
Excess weight concerns people in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, according to the health agency.
